AM 404 inhibits
endocannabinoid uptake and enhances the
cannabinoid CB(1)-mediated effects of endogenous
cannabinoids. Accumulating evidence also suggests that
AM 404 acts at sites other than the
endocannabinoid system. One site is the transient receptor potential vanilloid 1
cation channel (TRPV1). A useful endpoint for discriminating between TRPV1- or CB(1)-mediated effects of
AM 404 is
hypothermia. This is because TRPV1 or CB(1) receptor activation produces a significant
hypothermia in rats. The present study investigated the effects of
AM 404 (1, 5, 10 and 20 mg/kg, i.p.) on body temperature in rats and the involvement of TRPV1 and CB(1) receptors in the effects of
AM 404. Doses of 10 and 20 mg/kg of
AM 404 produced significant
hypothermia. Pre-treatment with
capsazepine (30 mg/kg, i.p.) blocked the
hypothermia caused by 10 and 20 mg/kg of
AM 404. Pre-treatment with
SB 366791 (2 mg/kg, i.p.), a new TRPV1 antagonist, also abolished the
hypothermia evoked by
AM 404 (20 mg/kg, i.p.). In contrast, pre-treatment with
SR 141716A (
Rimonabant), a CB(1) antagonist, or
AA-5-HT, a
fatty acid amide hydrolase (FAAH) blocker, did not affect AM 404-evoked
hypothermia. The present data demonstrate that
AM 404 evokes a significant
hypothermia in rats that is dependent on
TRPV1 receptor activation.